The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Nationwide Population-based Cohort Study With 30 Years of Follow-up Evaluation
Open accessAbstract
Background & Aims Data regarding the risk of gastrointestinal and extra-intestinal cancers in Crohn’s disease (CD) and ulcerative colitis (UC) are needed to understand the clinical course of inflammatory bowel diseases (IBDs) and their treatments. Methods We performed a nationwide historical cohort study using Danish healthcare databases. We identified patients with a diagnosis of CD or UC, recorded from 1978 through 2010, and followed them until first occurrence of cancer, death, or emigration. We used standardized incidence ratios (SIRs) to compare cancer incidence in CD and UC patients to that expected in the general population. Results Excluding cancers diagnosed within 1 year of IBD diagnosis, 772 cases of invasive cancer occurred among 13,756 patients with CD (SIR, 1.3; 95% confidence interval [CI], 1.2–1.4) and 2331 occurred among 35,152 patients with UC (SIR, 1.1; 95% CI, 1.0–1.1). CD was weakly associated with gastrointestinal cancers (SIR 1.2; 95% CI, 1.0–1.4) and extra-intestinal cancers (SIR, 1.3; 95% CI, 1.2–1.4), with the strongest associations for hematological malignancies (SIR, 1.9; 95% CI, 1.5–2.3), smoking-related cancers (SIR 1.5, 95% CI 1.3–1.8), and melanoma (SIR, 1.4; 95% CI, 1.0–1.9). Associations between UC and gastrointestinal and extra-intestinal cancers were weaker (SIR, 1.1; 95% CI, 1.0–1.2 and SIR, 1.1; 95% CI, 1.0–1.1, respectively). The relative risk of extra-intestinal cancers among patients with IBD was relatively stable over time, although the risk of gastrointestinal cancers decreased. Conclusions Patients with IBD, particularly CD, are at increased risk for gastrointestinal and extra-intestinal malignancies. The relative risk of gastrointestinal malignancy has deceased since 1978, without a concomitant increase in the risk of non-gastrointestinal malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Jess, T., Frisch, M., Jørgensen, K. T., Pedersen, B. V., & Nielsen, N. M. (2012) · Gut · doi:10.1136/gutjnl-2011-301095 · Cited by 148
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
The epidemiology of inflammatory bowel disease
Burisch, J., & Munkholm, P. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1014407 · Cited by 365
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Gordon, H., Biancone, L., Fiorino, G., Katsanos, K. H., Kopylov, U., Al Sulais, E., Axelrad, J. E., Balendran, K., Burisch, J., de Ridder, L., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac187 · Cited by 317
Innate Lymphoid Cells in Mucosal Immunity
Panda, S. K., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00861 · Cited by 275
Systematic review with meta‐analysis: the declining risk of colorectal cancer in ulcerative colitis
Castaño‐Milla, C., Chaparro, M., & Gisbert, J. P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12651 · Cited by 268
The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD
Bernstein, C. N., Benchimol, E. I., Bitton, A., Murthy, S. K., Nguyen, G. C., Lee, K., Cooke-Lauder, J., & Kaplan, G. G. (2019) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy053 · Cited by 81
Erichsen, R., Olén, O., Sachs, M. C., Pedersen, L., Halfvarson, J., Askling, J., Ekbom, A., Ludvigsson, J. F., & Sørensen, H. T. (2021) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1241 · Cited by 31
Self-citationZhang, H., Shi, Y., Song, Q., Li, N., Lin, Z., Chen, Q., Yang, Y., Chen, Y., Liu, Q., Tan, Y., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03636-2
Metadata
- Authors
- Kappelman, M. D., Farkas, D. K., Long, M. D., Erichsen, R., Sandler, R. S., Sørensen, H. T., & Baron, J. A.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 12
- Issue
- 2
- Pages
- 265-273.e1
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2025655642
- Cited by
- 248
- References
- 3
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.